Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cost-effective non-additive GWAS across 2329 diseases in 500,349 individuals. | Nat Commun | 2025 | 41390737 | PubTator, text mining | PubMed |
| Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study. | Mol Biomed | 2025 | 41364305 | PubTator, text mining | PubMed |
| Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. | Nat Commun | 2025 | 41350522 | PubTator, text mining | PubMed |
| CD160-Derived Peptide as a Bidirectional Inhibitor Toward Immune Checkpoints BTLA/HVEM and HVEM/LIGHT. | J Med Chem | 2025 | 41319234 | PubTator, text mining | PubMed |
| A bidirectional Mendelian randomization analysis of the causal relationship between immune cells and high-grade squamous intraepithelial lesion. | Medicine (Baltimore) | 2025 | 41305712 | PubTator, text mining | PubMed |
| Evaluation of LIGHT-derived peptides to disrupt the HVEM/LIGHT immune checkpoint. | Sci Rep | 2025 | 41249287 | PubTator, text mining | PubMed |
| A robust EMT-related prognostic model for ccRCC integrating single-cell and bulk transcriptome data. | Discov Oncol | 2025 | 41212297 | PubTator, text mining | PubMed |
| Comprehensive molecular analysis of uveal melanoma identifies targets in tumor-intrinsic and tumor-extrinsic pathways. | iScience | 2025 | 41210991 | PubTator, text mining | PubMed |
| HVEM-derived peptides as inhibitors of HVEM/LIGHT complex formation. | Bioorg Chem | 2025 | 41197453 | PubTator, text mining | PubMed |
| Intraepithelial Lymphocytes and LAIR1 Expression in Celiac Disease. | Biomedicines | 2025 | 41153806 | PubTator, text mining | PubMed |
| Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia. | Iran J Pharm Res | 2025 | 41104252 | PubTator, text mining | PubMed |
| Identification of Plasma Protein Biomarkers and Drug Targets for Hematologic Malignancies by Proteome-wide Mendelian Randomization. | J Cancer | 2025 | 41048997 | PubTator, text mining | PubMed |
| Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients. | Cancer Res Commun | 2025 | 41038711 | PubTator, text mining | PubMed |
| TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD. | Front Immunol | 2025 | 41030453 | PubTator, text mining | PubMed |
| Analysis of Immune Checkpoints on Peripheral Blood Mononuclear Cells Can Predict Clinical Outcome and Reveal Potential of HVEM-BTLA Axis in Epithelial Ovarian Cancers. | Pharmaceuticals (Basel) | 2025 | 41011166 | PubTator, text mining | PubMed |
| Novel Therapeutic Development for Nasopharyngeal Carcinoma. | Curr Oncol | 2025 | 41002550 | PubTator, text mining | PubMed |
| Exploration of potential novel drug targets for rheumatoid arthritis by plasma proteome screening. | PLoS Comput Biol | 2025 | 40996951 | PubTator, text mining | PubMed |
| FXR shapes an immunosuppressive microenvironment in PD-L1lo/- non-small cell lung cancer by upregulating HVEM. | JCI Insight | 2025 | 40985894 | PubTator, text mining | PubMed |
| Mendelian randomization analysis of immune cell traits and oral microbiota in nasopharyngeal carcinoma during radiotherapy. | Discov Oncol | 2025 | 40982168 | PubTator, text mining | PubMed |
| Unleashing the Antiviral Potential of Stapled Peptides: A New Frontier in Combating Human Neurotropic Viral Infections. | Microb Biotechnol | 2025 | 40955200 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=6